OSIR
$5.01
Osiris Therapeutics
$.09
1.83%
OSIR
Earnings Whisper ®
N/A
2nd Quarter June 2016
Consensus:  $0.00
Revenue:  N/A
Tuesday
May 10
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when OSIR reports earnings?
Beat
Meet
Miss

Where is OSIR's stock price going from here?
Up
Flat
Down
Stock chart of OSIR
Analysts
Summary of analysts' recommendations for OSIR
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.
Peers
Gilead SciencesAmgenBiogenBluebird BioQiagen N.V.Seattle GeneticsBioCryst PharmaceuticalsJuno TherapeuticsNeurocrine BiosciencesLa Jolla Pharmaceutical Compan